Vaxxinity

The new research is early, but it's a hopeful advance for patients with the neurological condition time.com/6883054/parkin…

Vaxxinity published data from an early-stage clinical trial showing that its investigative immunotherapy, UB-312, could improve movement in Parkinson’s disease and protect against pathological alpha-synuclein. #parkinsons #biospace hubs.li/Q02CGTgP0

In case you missed it... nature.com/articles/s4159…

We're going after the root cause of Parkinson's. time.com/6883054/parkin…

News from @vaxxinity and @UF on a #collaboration to advance #vaccine development for #neurodegenerative diseases like #parkinsons and #alzheimers. #vaccinenation #vaccines #disease #florida vaccinenation.org/therapeutic/va…

Under the agreement, @uf scientists will conduct preclinical studies exploring effects of vaccines for neurodegenerative diseases. See more: buff.ly/42zQokj #parkinsons #parkinsonsdisease #parkinsonsresearch #parkinsonstreatment

Check out our executive chairman @NotLouReese on Cheddar News Friday: Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market. cheddar.com/media/vaxxinit…

Vaxxinity Inc. will work with the University of Central Florida in Orlando to develop special new vaccines for astronauts that aim to prevent a common problem created during space exploration. Click for the details. bizjournals.com/orlando/news/2…

Could space travel research deliver a frailty vaccine? @vaxxinity and UCF collaborate on muscle and bone wasting immunotherapies to benefit both space exploration and human longevity. @NotLouReese #longevity #space #research #vaccine longevity.technology/news/could-spa…

Researchers return to Alzheimer's vaccines, buoyed by recent drug success reut.rs/3R3MQ5M

Our CEO, Mei Mei, has been recognized on the @PharmaVoice 100 list as an inspiring leader in the life-sciences space! #mei-mei-hu" target="_blank" rel="nofollow noopener">pharmavoice.com/news/pharmavoi…

Join us online next Monday, 9/11 at 10am ET! You won’t want to miss the latest corporate update from our CEO. Watch live here: journey.ct.events/view/7f32ae28-…

Looking forward to presenting in September. Our H.C. Wainwright presentation will be broadcast live to the public. Tune in! ir.vaxxinity.com/news-releases/…

Meet our Hidden Hero Rob Townley who work with some of our most complex and high risk projects at @Maersk👊Learn more about how Rob helps bring our #purpose to life⭐ 👉Watch the full video: youtu.be/i0KeZuW6wKw #Maersk #HiddenHero #alltheway #Career

Jean-Cosme Dodart (@vaxxinity) discussed recently published trial findings on a novel vaccine that targets Alzheimer's disease and triggers the production of antibodies against toxic amyloid-ß peptides. Watch here 👇 ow.ly/HBLP50PAV24

#ICYMI: Phase 1 trial results investigating UB-312 (@vaxxinity) revealed target engagement of aggregated alpha-synuclein in cerebrospinal fluid of patients with Parkinson disease. Read more: ow.ly/21hk50PusiP

Treatment with an investigational anti-#amyloid therapeutic for adults with mild #AD was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a @Vaxxinity study published in @eBioMedicine. bit.ly/3qqCAtU

Thought leader @DrJeffCummings sums up our latest publication in The Lancet’s @eBioMedicine about UB-311, the active vaccine candidate targeting beta-amyloid. ir.vaxxinity.com/news-releases/…

Vaxxinity - Expansively Disrupting Medicine Read more: bit.ly/3OnDFuF #ChronicDiseaseVaccines

Did you miss last week's fireside chat on vaccines for #dementia? If so, you can find the inspiring & informative 30-minute conversation with ADI's @WeidnerWendy, @AC_Immune_SA's Andrea Pfeifer & Mei Mei Hu of @vaxxinity, on our YouTube channel. youtu.be/h7A93G0HVxU